NCI grant allows Massey to expand community outreach efforts
VCU Massey Cancer Center was recently awarded a grant by the National Cancer Institute (NCI) to support the expansion of Massey’s outreach initiatives through the NCI’s National Outreach Network (NON) Community Health Educator (CHE) program. NON is one of two multidisciplinary programs within the NCI’s Integrated Networks Program (INP) that connects at-risk and underserved communities with NCI research, training and outreach efforts through trained CHEs located at partnering research sites.
Twitter chat on prostate cancer
Last week, the National Cancer Institute and the Men’s Health Network co-hosted a Twitter chat on prostate cancer. The discussion focused on the future of treatments for the disease, and VCU Massey Cancer Center hematologist-oncologist Asit Paul, M.D., Ph.D., with nurse practitioner Gwen Parker, M.S., FNP-C weighed in as the moderator posed a series of questions.
Darlene Brunzell named program leader of Cancer Prevention and Control
Darlene Brunzell, Ph.D., has been appointed the co-leader of the Cancer Prevention and Control (CPC) research program at VCU Massey Cancer Center. She will serve in this capacity alongside Jennifer Elston Lafata, Ph.D., who has co-led the program since 2010.
Massey researchers awarded grant to study the impact of e-cigarette advertising on youth
VCU Massey Cancer Center researchers Andrew Barnes, Ph.D., and Caroline Cobb, Ph.D., were recently awarded a $450,000 grant from the Virginia Foundation for Healthy Youth (VFHY) to study the impact of electronic cigarette advertising on youth ages 13-18. The results of the study will help inform policy makers as they determine whether the marketing of e-cigarettes should be regulated in the same fashion as their combustible cigarette counterparts.
Massey researcher awarded nearly $1 million to develop a clinical trial to test a new AML therapy
VCU Massey Cancer Center researcher Steven Grant, M.D., was awarded nearly $1 million in grant funding from the National Center for Advancing Translational Sciences (NCATS) to support the development of a clinical trial that will test a novel, experimental therapy for acute myeloid leukemia (AML, an aggressive blood cancer) that he co-discovered.